Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
JAMA Oncol. 2017 Dec 1;3(12):1640-1645. doi: 10.1001/jamaoncol.2017.1350.
Establishment of an optimal cancer surveillance program is important to reduce cancer-related morbidity and mortality in individuals with Li-Fraumeni syndrome, a rare, highly penetrant cancer predisposition syndrome.
To determine the feasibility and efficacy of a comprehensive cancer screening regimen in Li-Fraumeni syndrome, using multiple radiologic techniques, including rapid whole-body magnetic resonance imaging (MRI) and laboratory measurements.
DESIGN, SETTING, AND PARTICIPANTS: Baseline evaluation of a prospective cancer screening study was conducted from June 1, 2012, to July 30, 2016, at the National Cancer Institute, National Institutes of Health (an academic research facility). Participants included 116 individuals with Li-Fraumeni syndrome with a germline TP53 pathogenic variant who were aged 3 years or older at the time of baseline screening and had not received active cancer therapy at least 6 months prior to screening.
Detection of prevalent cancer with multimodal screening techniques and the need for additional evaluation.
Of the 116 study participants, 77 (66.4%) were female; median age was 37.6 years (range, 3-68 years). Baseline cancer screening led to the diagnosis of cancer in 8 (6.9%) individuals (2 lung adenocarcinomas, 1 osteosarcoma, 1 sarcoma, 1 astrocytoma, 1 low-grade glioma, and 2 preinvasive breast cancers [ductal carcinoma in situ]); all but 1 required only resection for definitive treatment. A total of 40 (34.5%) participants required additional studies to further investigate abnormalities identified on screening, with 32 having incidental, benign, or normal findings, resulting in a false-positive rate of 29.6%. Non-MRI techniques, including baseline blood tests, abdominal ultrasonography in children, mammography, and colonoscopy, did not lead to a diagnosis of prevalent cancer in our cohort.
This study describes the establishment and feasibility of an intensive cancer surveillance protocol for individuals with Li-Fraumeni syndrome. Prevalent cancers were detected at an early stage with baseline whole-body, brain, and breast MRI. Prospective screening of the participants is under way.
建立最佳的癌症监测计划对于减少 Li-Fraumeni 综合征患者的癌症相关发病率和死亡率至关重要,Li-Fraumeni 综合征是一种罕见的、高外显率的癌症易感性综合征。
使用多种影像学技术(包括快速全身磁共振成像 [MRI] 和实验室测量),确定 Li-Fraumeni 综合征综合癌症筛查方案的可行性和疗效。
设计、地点和参与者:2012 年 6 月 1 日至 2016 年 7 月 30 日,在国立癌症研究所,美国国立卫生研究院(学术研究机构)进行了前瞻性癌症筛查研究的基线评估。参与者包括 116 名 Li-Fraumeni 综合征患者,他们携带种系 TP53 致病性变异,在基线筛查时年龄在 3 岁或以上,且在筛查前至少 6 个月未接受过主动癌症治疗。
多模态筛查技术检测到的现患癌症以及进一步评估的需求。
在 116 名研究参与者中,77 名(66.4%)为女性;中位年龄为 37.6 岁(范围,3-68 岁)。基线癌症筛查导致 8 名(6.9%)个体确诊癌症(2 例肺腺癌、1 例骨肉瘤、1 例肉瘤、1 例星形细胞瘤、1 例低级别胶质瘤和 2 例乳腺导管原位癌);除 1 例外,所有患者仅通过切除即可进行确定性治疗。共有 40 名(34.5%)参与者需要进一步研究来进一步调查筛查中发现的异常,其中 32 名有偶然的、良性或正常发现,假阳性率为 29.6%。非 MRI 技术,包括基线血液检查、儿童腹部超声检查、乳房 X 线摄影和结肠镜检查,并未导致我们队列中现患癌症的诊断。
本研究描述了为 Li-Fraumeni 综合征患者建立和实施强化癌症监测方案的情况。通过基线全身、脑部和乳房 MRI 早期检测到现患癌症。正在对参与者进行前瞻性筛查。